COMBINATION BRAF AND MEK INHIBITOR THERAPY FOR REDIFFERENTIATION OF RADIOIODINE REFRACTORY BRAF MUTATED PAPILLARY THYROID CANCER: A CASE STUDY

被引：0
|
作者：
Daw, N. [1 ]
Iravani, A. [1 ,2 ]
机构：
[1] Peter Maccallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2021年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：41 / 41
页数：1
相关论文
共 50 条
  • [41] Successful Combination Therapy of BRAF- and MEK-Inhibitor after Progress under BRAF-Inhibitor Mono Therapy: Report of a Patient with brain metastatic Melanoma
    Asper, H.
    Satger, I
    Tolk, H.
    Kapp, A.
    Gutzmer, R.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 166 - 166
  • [42] Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma
    Homan, Morgan
    Warrier, Govind
    Lao, Christopher D.
    Yentz, Sarah
    Kraft, Shawna
    Fecher, Leslie A.
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [43] Pharmacodynamic study of neoadjuvant vemurafenib (VEM) in patients (pts) with BRAF mutated, locally advanced papillary thyroid cancer (PTC).
    Cabanillas, Maria E.
    Holsinger, F. Christopher
    Sturgis, Erich M.
    Habra, Mouhammed Amir
    Davies, Michael A.
    Munsell, Mark F.
    French, Jena
    Busaidy, Naifa
    Hu, Mimi I-Nan
    Sherman, Steven I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience
    Irene Russo
    Ludovica Zorzetto
    Anna Chiara Frigo
    Vanna Chiarion Sileni
    Mauro Alaibac
    [J]. European Journal of Dermatology, 2017, 27 : 482 - 486
  • [45] A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan
    Tahara, Makoto
    Kiyota, Naomi
    Imai, Hiroo
    Takahashi, Shunji
    Nishiyama, Akihiro
    Tamura, Shingo
    Shimizu, Yasushi
    Kadowaki, Shigenori
    Ito, Ken-ichi
    Toyoshima, Masahiro
    Hirashima, Yoshinori
    Ueno, Shinji
    Sugitani, Iwao
    [J]. THYROID, 2024, 34 (04) : 467 - 476
  • [46] A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience
    Russo, Irene
    Zorzetto, Ludovica
    Frigo, Anna Chiara
    Sileni, Vanna Chiarion
    Alaibac, Mauro
    [J]. EUROPEAN JOURNAL OF DERMATOLOGY, 2017, 27 (05) : 482 - 486
  • [47] Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
    Booth, Andrew E. C.
    Hopkins, Ashley M.
    Rowland, Andrew
    Kichenadasse, Ganessan
    Smith, Justine R.
    Sorich, Michael J.
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [48] Genomic profiling and outcomes of BRAF V600E mutated papillary thyroid cancer.
    Shaikh, Hira
    McGrath, Julie
    Brodskiy, Pavel
    Xiu, Joanne
    Ikpeazu, Chukwuemeka
    Leddon, Jennifer
    Sukari, Ammar
    Zandberg, Dan Paul
    Abraham, Jim
    Wise-Draper, Trisha Michel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18086 - E18086
  • [49] Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids
    Hélène Lasolle
    Andrea Schiavo
    Adrien Tourneur
    Pierre Gillotay
    Bárbara de Faria da Fonseca
    Lucieli Ceolin
    Olivier Monestier
    Benilda Aganahi
    Laura Chomette
    Marina Malta Letro Kizys
    Lieven Haenebalcke
    Tim Pieters
    Steven Goossens
    Jody Haigh
    Vincent Detours
    Ana Luiza Silva Maia
    Sabine Costagliola
    Mírian Romitti
    [J]. Oncogene, 2024, 43 : 155 - 170
  • [50] Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids
    Lasolle, Helene
    Schiavo, Andrea
    Tourneur, Adrien
    Gillotay, Pierre
    de Faria da Fonseca, Barbara
    Ceolin, Lucieli
    Monestier, Olivier
    Aganahi, Benilda
    Chomette, Laura
    Kizys, Marina Malta Letro
    Haenebalcke, Lieven
    Pieters, Tim
    Goossens, Steven
    Haigh, Jody
    Detours, Vincent
    Maia, Ana Luiza Silva
    Costagliola, Sabine
    Romitti, Mirian
    [J]. ONCOGENE, 2024, 43 (03) : 155 - 170
12345